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Abstract  
Introduction 
Standard assessment of renal function in pregnancy is by measurement of serum 
creatinine concentration yet normal gestational ranges have not been established. 
The aim of this systematic review was to define the difference in serum creatinine in 
healthy pregnancy compared to concentrations in non-pregnant women to facilitate 
identification of abnormal kidney function in pregnancy.  
Methods 
Medline, PubMed, Embase, Web of Science™, theses, key obstetric texts and 
conference proceedings were searched to July 2017. Eligible studies included 
quantification of serum creatinine concentration in a pregnant cohort, with either a 
reported local laboratory reference range or matched quantification in a non-
pregnant cohort. The outcomes of interest were the mean and upper reference 
limits for creatinine in pregnancy, measured as a ratio of pregnant:non-pregnant 
values. Study heterogeneity was examined by meta-regression analysis.  
Results 
Forty-nine studies were identified. Data synthesis included 4421 serum creatinine 
values in pregnancy, weighted according to cohort size. Mean values for serum 
creatinine in pregnancy were 84%, 77% and 80% of non-pregnant mean values 
during the first, second and third trimesters respectively.  The 97.5th centile (upper 
limit of the 95% reference range) for serum creatinine in pregnancy was 85%, 80% 
and 86% of the non-pregnant upper limit in sequential trimesters.  
Conclusions 
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Based on a non-pregnant reference interval of 45-90µmol/L [0.51-1.02mg/dL], a 
serum creatinine of >77µmol/L [0.87mg/dL] should be considered outside the 
normal range for pregnancy. Future work can use this value to explore correlation of 
adverse pregnancy outcomes with serum creatinine concentration.  
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Introduction  
Outside of pregnancy, glomerular filtration rates are routinely estimated from serum 
creatinine concentrations using standardised equations, facilitating the diagnosis of 
chronic kidney disease (CKD) and grading of disease severity. Such equations use 
demographic and clinical variables to correct for physiological factors that affect 
serum creatinine. However, in pregnancy, estimated glomerular filtration rates 
(eGFR) inconsistently underestimate renal function function and should not be 
used.1 eGFR calculations based on Modified Diet in Renal Disease (MDRD) 
calculations underestimate GFR in pregnancy by up to 41ml/min/1.73m2 compared 
with inulin clearance.2 Even in women with pre-eclampsia and contracted maternal 
plasma volume, eGFR remains inaccurate when derived by both MDRD and Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) methods, compared with inulin 
and creatinine clearance.2,3 
 
Serum creatinine concentration therefore remains the only standard, single-point 
assessment for kidney function in pregnant populations, yet a normal range for 
serum creatinine in pregnancy has not been established. The upper limit (95th-97.5th 
centile) of creatinine concentration in healthy pregnancy varies between published 
cohorts. Reference range limits include values of 72µmol/L [0.81mg/dL],4 80µmol/L 
[0.90mg/dL],5 89µmol/L [1.00mg/dL]6 and 95µmol/L [1.07mg/dL].7 Such data have 
limited generalizability without correction for factors known to cause variance in 
serum creatinine including ethnicity, gestation, and the use of different creatinine 
assay methods. The most widely cited study of trimester-specific creatinine 
concentration includes only 29 healthy pregnant women.7 Contemporaneous 
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statements regarding creatinine concentration in pregnancy are largely based on 
expert opinion including a ‘normal’ range of 35-71µmol/L [0.40-0.80mg/dL],8,9 an 
‘average’ creatinine in pregnancy of 53µmol/L [0.60mg/dL],10 and a recommendation 
that serum creatinine in pregnancy greater than 75µmol/L [0.85mg/dL] should raise 
suspicion of kidney injury.11 
 
We report here a systematic review of studies including serum creatinine 
concentrations in healthy pregnancy. Serum creatinine concentrations measured in 
pregnant cohorts were compared with either a local laboratory reference interval or 
with creatinine concentrations derived from a matched non-pregnant cohort. The 
objective of the study was to compare serum creatinine concentration in pregnancy 
(‘exposed’ cohort) with non-pregnant (‘unexposed’) via calculation of a ratio of 
pregnant:non-pregnant serum creatinine. The hypothesis of the study was that 
serum creatinine concentrations in pregnancy can be estimated as a proportion of 
matched non-pregnant values, thereby eliminating variation due to assay method 
and ethnicity, and allowing generation of generalisable normal reference ratios for 
serum creatinine concentration in pregnancy.  
 
Methods 
Data sources and searches were conducted by two authors with training in (KW, KB), 
and experience of (KB), systematic review methodology. Medline, PubMed and 
Embase were searched for first publication to July 2017. Search terms included 
creatinine, glomerular filtration, GFR, MDRD, Cockcroft, renal function, kidney 
function, biochemistry, clinical chemistry in combination with pregnan$, trimester, 
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gestat$. Specific search strategies are detailed in the supplementary material. A 
search of conference proceedings specific to the field of obstetrics and gynaecology, 
as classified by Web of Science™, was also completed. A hand search was 
undertaken of key English obstetric textbooks for creatinine reference ranges in 
pregnancy and the sources for these data were included where available. A search 
for academic theses relevant to pregnancy was performed via proquest.com and 
ethos.bl.uk.  
 
Citations were independently screened by two authors (KW, KB) based on the title 
and abstract. Non-English language articles were included if a translation of the 
abstract into English was available. A full text review was carried out on all eligible 
studies, and where eligibility was uncertain from the title or abstract. If a control 
population was not reported, study authors were contacted to provide relevant local 
laboratory reference ranges for the creatinine assay used at the time their study was 
conducted.  
 
Only studies reporting a local laboratory serum creatinine concentration reference 
interval or cohort data from a non-pregnant population, and including a measure of 
data spread across the cohort (standard deviation, standard error, interquartile 
range, centile, or normal range) were eligible. Gestational age at the time of serum 
creatinine measurement was required for analysis of creatinine data according to 
trimester. Studies that included pregnant women with kidney disease (upper 
reference range for creatinine in control population >125µmol/L [1.41mg/dL]), 
vascular disease, diabetes and adverse pregnancy outcome including pre-eclampsia 
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were excluded. Any study that did not adequately describe the health of population 
studied was excluded, as ‘normality’ in the population could not be presumed. 
Studies were also excluded if serum creatinine concentrations were assessed in a 
non-pregnant cohort at less than 6 weeks post-partum.  
 
Methodological quality of the studies was scored using the Newcastle-Ottawa scale 
for observational cohort studies.12 This included measures of how representative 
both the pregnant and non-pregnant cohorts were of ‘average’ women of 
childbearing age in the community, the exclusion of CKD, and whether data were 
adequately controlled for pregnancy pathology including pre-eclampsia. 
 
Data were extracted in duplicate by two authors (KW, KB) working independently 
using a proforma based on the study inclusion criteria. Author, publication year, 
study type (longitudinal/cross sectional), ethnicity, laboratory method for 
determination of serum creatinine, definition of control population, definition of 
normal pregnancy, gestation in weeks, and creatinine values including measures of 
data spread (standard deviation/error or centile) were recorded. Where cohort 
ethnicity was not given, black and non-black ethnicity was assigned based upon the 
population demographic of the country in which the study took place. 
Disagreements were resolved by discussion between two authors (KW, KB), with 
arbitration from a third author (LC).  
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We defined exposure as pregnancy, and gestation at sample collection was 
recorded. To enable comparison, creatinine measures were converted from mg/dL 
to µmol/L using a conversion factor of 88.42.  
 
A normal distribution of serum creatinine concentrations was assumed based on 
previously published cohort data both in non-pregnant13-16 and pregnant6,17 cohorts. 
Mean creatinine concentrations in the pregnant and non-pregnant cohorts were 
extracted from the raw data, or derived from the median or reference range on the 
assumption of a normal distribution. Similarly, creatinine reference intervals for both 
pregnant and non-pregnant cohorts were obtained from the available raw data or a 
97.5th centile (upper limit of the 95% reference range) was calculated as the mean 
value + 1.96 standard deviations.  
 
Data were divided by trimesters of pregnancy (<13 weeks, 13-26 weeks, >26 weeks 
gestation). Where a range of gestation was included within the data, data were 
allocated to the trimester for which the gestational range was most representative. 
If studies included more than one measure of creatinine in the same trimester,  
mean values for each trimester were calculated. Mean and upper reference values 
for creatinine concentration in pregnancy were converted to a proportion 
(percentage) of the equivalent value from either the non-pregnant cohort described 
in each study, or the mean and upper reference limit of the given local reference 
range. A bootstrapping method (described below) was then used to provide a 
combined estimate for each trimester.  
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Statistical analysis was performed using Stata version 14.2. We used the calculation 
of the I2 statistic18,19 to test for heterogeneity in the pregnant:non-pregnant ratio 
between studies. Where heterogeneity was found, meta-regression was used to 
assess whether the differences between studies was due to the use of cross-
sectional data, year of publication, the specific exclusion of renal disease, Jaffe and 
enzymatic methods of creatinine measurement, or black ethnicity. This was done by 
separate linear regression of each variable, in each trimester, with impact on the 
pregnant:non-pregnant creatinine ratio measured as a coefficient value.  Year of 
publication was analysed as a continuous measure and by conversion to decade. 
Analytic weights were defined by Stata.  
 
The calculation of pregnant:non-pregnant creatinine ratios meant that standard 
error measurements were not available, with no accepted method to estimate this 
quantity from summary data. The complexity of determining the variance and 
distribution of a ratio value meant we were unable to use most standard meta-
analysis techniques including DerSimonian and Laird estimates of the combined 
effect, Forest plots, and an assessment of publication bias.20 Data from the included 
studies were therefore synthesised using a bootstrapping technique. This involved 
repeat sampling (10,000 repetitions) with each study acting as a single observation. 
Bootstrapping was informed by the assessment of heterogeneity and the results of 
the meta-regression. Heterogeneity between studies was high (I2>99%). The 
inclusion of studies using a reference range as the non-pregnant comparator 
revealed an irreconcilable heterogeneity of data which prevented meaningful 
synthesis. Heterogeneity was however reduced (I2=12.3) when the pregnant:non 
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pregnant ratio was examined using studies with a large (>100 women) non-pregnant 
cohort.  Meta-regression revealed the importance of pregnant cohort size. The 
bootstrapping technique therefore included all studies with a non-pregnant cohort, 
weighted according to the product of the geometric mean of pregnant and non-
pregnant cohort size. Bias-corrected confidence intervals were generated using an 
automatic algorithm, which estimates and corrects for bias in the sampling process.21  
 
This systematic review was registered on the PROSPERO database with registration 
number CRD42017068446.   
 
Results 
Electronic searching identified 3297 unique citations including 11 sources identified 
by hand searching of textbooks. Of the 3267 available sources, we excluded 3033 
sources on the basis of title and abstract review. The majority of excluded papers 
were studies of urinary creatinine concentration in pregnancy usually performed as 
part of a urinary protein:creatinine ratio in pre-eclampsia, and did not include serum 
creatinine measurement. Studies of amniotic, fetal or neonatal creatinine 
measurement were also excluded.  A further 185 sources were excluded after full-
text review (Figure 1). Four studies were included after contacting the authors to 
provide local laboratory reference ranges at the time of their study . 
 
 
Forty-nine studies were included in the analysis. Study characteristics including 
reference details, ethnicity, study type, sample size, trimester specific creatinine 
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measurements, creatinine assay method,  assessment of normal pregnancy and  the 
Newcastle-Ottawa assessment of study quality are reported in Table 1.    
 
Median pregnant cohort sizes were 40, 40 and 35 in the first, second and third 
trimesters respectively (interquartile range 17-67). Of the 49 included studies, only 
nine had creatinine concentrations from more than 100 women within the same 
trimester. Detail regarding the specific exclusion of renal disease was made in 22 
studies.  
 
Non-pregnant control cohorts were the ‘unexposed’ comparator in 39 studies. The 
median non-pregnant cohort size was 19 women (interquartile range 13-52). Only 
three studies included more than 100 non-pregnant women in the control cohort. 
Serum creatinine in pregnancy was compared to a laboratory reference interval in 10 
studies. No details were available regarding how these laboratory reference intervals 
had been derived and whether they were specific to a female population.  
 
Most studies had limited reporting of creatinine assay methods. Creatinine was 
quantified using the Jaffe reaction in 24 studies and by a kinetic enzymatic reaction 
in 11 studies. Assay method was not available for 14 studies. Inter-assay precision 
was reported in only 10 studies. No studies documented whether creatinine assay 
methods were traceable to an isotope dilution mass spectometry (IDMS) reference, 
according to current recommendation.22  
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Study quality was variable. In 19 of the 49 studies ‘normal’ pregnancy was confirmed 
after completion of the pregnancy, with exclusion of data from women who 
experienced an abnormal pregnancy. However quality scores ranged from 4-9 on the 
Newcastle-Ottawa scale based on selection, comparability and outcome. Based on 
previously described thresholds for quality assessment,23 only 11 of the 49 studies 
were classified as ‘good’ quality for this systematic review.  
 
Meta-regression demonstrated that the size of the pregnant cohort had a significant 
impact on the pregnant:non-pregnant creatinine ratio across all three trimesters. 
The use of cross-sectional data, year and decade of publication, the specific 
exclusion of renal disease, creatinine assay method, and black ethnicity showed no 
significant effect on the ratio result (Table 2).  
 
Data synthesis included all studies which had a matched pregnant control cohort as 
the non-pregnant comparator. This included 816 creatinine values (19 studies) from 
the first trimester, 1183 creatinine values (22 studies) from the second trimester, 
and 2422 creatinine values (30 studies) from the third trimester. Mean values for 
serum creatinine in pregnancy were 84% (95% confidence interval 76%-90%), 77% 
(72%-83%), and 80% (77%-84%) of mean values outside of pregnancy during the 
first, second and third trimesters respectively. Using the 97.5th centile (upper limit of 
the 95% reference range), serum creatinine in pregnancy was 85% (76%-93%), 80% 
(73%-89%), and 86% (83%-89%) of the upper reference limit for non-pregnant 
females in sequential trimesters (Table 3, Figure 2).  
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Discussion 
Data synthesis from this systematic review creates a mean and upper reference limit 
for serum creatinine in pregnancy, compared to non-pregnant values. Mean serum 
creatinine in pregnancy is 77-84% of mean values outside of pregnancy, and the 
reference limit for serum creatinine is 80-86% of that in non-pregnant women. Based 
on a normal female range for serum creatinine of 45-90µmol/L [0.51-1.02mg/dL],24 
this equates to mean serum creatinine values of 56µmol/L [0.63mg/dL], 52µmol/L 
[0.59mg/dL] and 54µmol/L [0.61mg/dL] in sequential trimesters, whilst serum 
creatinine values greater than 76µmol/L [0.86mg/dL] in the first trimester, 72µmol/L 
[0.81mg/dL] in the second trimester, and 77µmol/L [0.87mg/dL] in the third 
trimester should be considered to be outside the upper limit of normal for 
pregnancy. A serum creatinine greater than 77µmol/L [0.87mg/dL] in pregnancy 
should raise the possibility of either acute kidney injury (AKI), or undiagnosed CKD 
predating the pregnancy.  
 
As far as we are aware, this is the only study published to date that attempts to offer 
a value for serum creatinine in pregnancy which is generalizable and not limited to a 
specific population or creatinine assay technique. The strength of this study is that, 
through the use of a ratio of pregnant to non-pregnant values, it provides a synthesis 
of published creatinine data from multiple normal pregnant cohorts, across different 
ethnicities and assay techniques. Previous reports of creatinine concentration 
according to gestation are limited by small numbers of women, diverse methodology 
and insufficient information about disease states in ‘normal women’.   
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The main limitation of this study is in the amount of heterogeneity in the included 
data. This is likely to be due to a combination of both study design and clinical 
factors. The complexity of generating standard deviation or standard error values for 
a ratio value20 means that the precision of each study is not considered in the meta-
analysis. In addition, creatinine data are summarised as single value for each 
trimester which may fail to adequately represent the true variation in serum 
creatinine for individual pregnant women, including a progressive physiological 
adaption to both early pregnancy and parturition. 25-28 
 
Heterogeneity was reduced when the ratio of pregnant:non-pregnant creatinine 
used a matched non-pregnant cohort, compared to ratios generated from laboratory 
reference intervals. This is likely due to quantification in a control population being 
performed over the same time period as the samples taken during pregnancy, 
conferring less analytical variance and better reproducibility of values.29  In contrast, 
heterogeneity when using a laboratory reference range as the non-pregnant 
comparator may have arisen due to baseline differences between the reference and 
pregnant cohorts including gender, age and ethnicity; although there was insufficient 
information on the generation of the reference intervals in the included studies to 
allow assessment of this.  
 
Meta-regression showed no significant difference in the pregnant:non-pregnant 
creatinine ratio related to the use of alkaline picrate (Jaffe) or enzymatic assay 
method. This suggests that either the two techniques are affected by pregnancy 
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equally, or that differences between assay techniques are insignificant relative to the 
effect of pregnancy on serum creatinine concentration. However, dichotomisation 
by assay technique may be overly simplistic. This review includes internationally 
diverse studies, performed over a 34-year period.  Although the majority of studies 
used a Jaffe method, this is known to lack standardisation, resulting in significant 
methodological variation, which is not measurable in this study.30 Confirmation of 
the findings of this systematic review using IDMS traceable creatinine assay 
methods22 is warranted.  
 
The results of this study concur with the known physiological changes of pregnancy; 
namely a fall in serum creatinine due to gestational hyperfiltration resulting in a 50% 
increase in creatinine clearance by the second trimester, 26-28 followed by a decrease 
in creatinine clearance during the third trimester25 leading to an increase in serum 
creatinine concentration towards term. This study suggests that the normal range for 
creatinine in pregnancy is either comparable to,4 or lower5-7 than that derived from 
other published cohorts, which are limited by assay method, ethnic differences in 
creatinine, and small cohort sizes.  
 
The synthesis of data in this study generated a mean value and upper reference 
range limit for creatinine in pregnancy as a relative proportion of a matched non-
pregnant cohort. In practice, clinicians have access to a laboratory reference range 
for creatinine, rather than a matched control value. For example, at the authors’ 
institution (Guy’s and St. Thomas NHS Foundation Trust), the female-specific 
reference interval for serum creatinine is 45-90µmol/L [0.51-1.02mg/dL]. This is 
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derived from 269 healthy, Red Cross blood donors.24  Although gender specific, this 
reference interval is not specific for women of child-bearing age as the reference 
population is aged 18-70 years. However, the use of this reference interval to derive 
values for child-bearing age women can be justified on the basis that an increased 
prevalence of silent chronic kidney disease with age is potentially counterbalanced 
by a simultaneous age-related decline in creatinine synthesis,31 with minimal effect 
on absolute serum creatinine values. Indeed, serum creatinine values have been 
shown to be stable in female, white European populations between the ages of 20 
and 70 years.14   However, the generation of an upper limit for serum creatinine in 
pregnancy through conversion of a local reference range will always be subject to 
the limitations under which that reference range was generated, and whether that 
reference interval is appropriately matched for gender and ethnicity.  
 
Acute kidney injury occurs most commonly during pregnancy in the third trimester, 
predominantly due to the development of hypertensive disorders and puerperal 
pathologies including sepsis and haemorrhage.32-35 Diagnostic criteria for AKI do not 
exist in pregnancy and up to 40% of pregnancy-associated AKI may be missed by 
clinicians in the UK.36 In this study, the upper reference limit for serum creatinine in 
the third trimester is based on data from 30 studies including 2422 pregnant women. 
Based on a non-pregnant upper limit for creatinine of 90µmol/L [1.02mg/dL],24 a 
new serum creatinine of >77µmol/L [0.87mg/dL] should trigger investigation for 
underlying AKI.   
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This study generated a mean and upper reference limit for creatinine in pregnancy, 
as a percentage of that outside of pregnancy. In the absence of both a valid measure 
of eGFR and practical measure of true GFR in pregnancy, the assessment of renal 
function in pregnant women remains limited to serum creatinine despite 
confounders, insensitivity, and inter-assay variability. However, the use of creatinine 
thresholds of 85%, 80% and 86% of the upper limit of the non-pregnant reference 
range for the first, second and third trimesters respectively, represents a new and 
clinically relevant diagnostic parameter, which is potentially generalisable across 
different cohorts and creatinine assays methods.  
 
A clinically relevant reference interval distinguishes physiology from pathology. The 
clinical utility of the pathological threshold suggested by this systematic review now 
requires prospective studies which correlate a creatinine in pregnancy that is >86% 
of the upper limit for non-pregnant females with adverse maternal and/or neonatal 
outcomes. Whether a similar percentage change in serum creatinine in pregnancy is 
seen in women with chronic kidney disease remains unknown, although a failure of 
serum creatinine to fall in the first trimester of pregnancy is hypothesised to 
represent a failure of the renal system to adapt in pregnancy and is used anecdotally 
as a poor prognostic indicator.37 Future research is required into patterns of serum 
creatinine change in women with chronic kidney disease who do and do not develop 
adverse pregnancy outcomes.  
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sectional 
Control Trimester 1 Trimester 2 Trimester 3 Creatinine 
assay 
method 
Assessment 
of pregnancy 
normality* 
Normal 
pregnancy 
outcome 
confirmed 
Newcastle-
Ottowa 
grade n 
Mean 
Cr 
ULN n 
Mean 
Cr 
ULN n 
Mean 
Cr 
ULN n 
Mean 
Cr 
ULN 
Afolabi
38
 2011 Nigeria C 15 
58 
[0.65] 
80 
[0.90]    
9 
61 
[0.69] 
93 
[1.05] 
3 
57 
[0.64] 
104 
[1.18] 
Jaffe 
1 
 6 
Akbari
39
 2005 Canada C 13 
74 
[0.84] 
86 
[0.97]    
68 
52 
[0.59] 
69 
[0.78] 
68 
54 
[0.61] 
78 
[0.88] 
Not stated 
2 
 7 
Al Kuran
40
 2012 Jordan L LRR 
70 
[0.79] 
96 
[1.10] 
797 
67 
[0.76] 
97 
[1.10] 
797 
64 
[0.72] 
100 
[1.13] 
797 
72 
[0.81] 
132 
[1.4] 
Jaffe 
2 
 6 
Babay
41
 2005 Saudi Arabia C 40 
58 
[0.66] 
71 
[0.80] 
54 
56 
[0.63] 
75 
[0.85] 
53 
57 
[0.64] 
81 
[0.92] 
50 
52 
[0.59] 
70 
[0.79] 
Not stated 
3 
Yes 8 
Babu
42
 2013 India C LRR 
71 
[0.80] 
78 
[0.88]       
25 
52 
[0.59] 
70 
[0.79] 
Not stated 
3 
 4 
Chapman
28
 1998 WE:AC=10:1 L 13 
71 
[0.80] 
88 
[1.00] 
10 
65 
[0.74] 
77 
[0.87] 
8 
53 
[0.60] 
73 
[0.83] 
8 
49 
[0.55] 
68 
[0.77] 
Jaffe 
3 
 8 
Collins
43
 1981 Canada C 65 
71 
[0.80] 
88 
[1.00]       
350 
53 
[0.60] 
71 
[0.80] 
Jaffe 
1 
 6 
Davison
25 
1980 UK L 10 
69 
[0.78] 
104 
[1.18]       
10 
60 
[0.68] 
104 
[1.18] 
Enzymatic 
3 
Yes 9 
Davison
26 
1981 UK L 9 
72 
[0.81] 
85 
[0.96] 
9 
64 
[0.72] 
77 
[0.87] 
9 
57 
[0.64] 
69 
[0.78]    
Enzymatic 
3 
Yes
+ 
8 
Djordjevic
44
 2004 
Serbia-
Montenegro 
L 30 
61 
[0.69] 
83 
[0.94] 
30 
65 
[0.74] 
91 
[1.03]       
Not stated 
1 
 7 
Duvekot
45
 1995 Netherlands L 10 
56 
[0.63] 
63 
[0.71] 
10 
53 
[0.60] 
68 
[0.77]       
Not stated 
1 
Yes 6 
Fasshauser
46
 2008a Germany C LRR
$
 
76 
[0.86] 
104 
[1.18]       
20 
55 
[0.62] 
79 
[0.89] 
Not stated 
1 
 5 
Fasshauser
47
 2008b Germany C LRR
$
 
76 
[0.86] 
104 
[1.18]       
20 
54 
[0.61] 
79 
[0.89] 
Not stated 
3 
 5 
de Flamingh
48
 1984 South Africa C 16 
74 
[0.84] 
88 
[1.00] 
10 
61 
[0.69] 
75 
[0.85] 
10 
55 
[0.62] 
71 
[0.80] 
40 
54 
[0.61] 
93 
[1.05] 
Not stated 
3 
 4 
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Girling
6
 2000 
47% WE, 
21% AC, 10% 
Med 
C LRR
$
 
88 
[1.00] 
120 
[1.36] 
20 
68 
[0.77] 
84 
[0.95] 
271 
63 
[0.71] 
125 
[1.41] 
68 
54 
[0.61] 
97 
[1.10] 
Jaffe 
3 
 6 
Guo
49
 2012 China L LRR
$
 
89 
[1.00] 
115 
[1.30]    
96 
42 
[0.48] 
52 
[0.59] 
96 
54 
[0.61] 
70 
[0.79] 
Jaffe 
3 
 4 
Hanna
50
 2009 Iraq C 40 
84 
[0.95] 
121 
[1.37] 
40 
83 
[0.94] 
118 
[1.33] 
40 
75 
[0.85] 
94 
[1.06] 
40 
54 
[0.61] 
92 
[1.04] 
Jaffe 
3 
 7 
Heguilén
51
 2007 Argentina C 8 
82 
[0.93] 
102 
[1.15]    
5 
66 
[0.75] 
88 
[1.00]    
Not stated 
3 
 4 
Iqbal
52 
2003 Pakistan C 26 
72 
[0.81] 
89 18 
65 
[0.74] 
95 22 
70 
[0.79] 
94 
 
23 
69 
[0.78] 
94 
Jaffe 
1 
 6 
Järnfelt-
Samsioe
53
^
 1985 Sweden C LRR 
80 
[0.90] 
110 
[1.24]    
37 
68 
[0.77] 
94 
[1.06] 
34 
66 
[0.75] 
94 
[1.06] 
Not stated 
2 
Yes
+
 4 
Jaing
54
 2013 Italy C 19 
53 
[0.70] 
66 
[0.75]       
29 
42 
[0.48] 
58 
[0.66] 
Not stated 
1 
Yes 7 
Kametas
55
# 2003 Peru C 13-15 
55-63 
[0.62-
0.71] 
68-80 
[0.77-
0.90] 
   
77-
80 
47-56 
[0.53-
0.63] 
58-74 
[0.66-
0.83] 
   
Jaffe 
2 
Yes 6 
Klajnbard
56
 2010 
Denmark 
(WE) 
L LRR 
70 
[0.79] 
90 
[1.02]    
532 
58 
[0.66] 
73 
[0.83] 
358 
62 
[0.70] 
84 
[0.95] 
Enzymatic 
2 
Yes 7 
Knopp
57
 1985 USA (WE) C 77 
67 
[0.76] 
88 
[1.00]       
546 
51 
[0.58] 
78 
[0.88] 
Jaffe 
1 
 5 
Koetje
1 
2011 
Netherlands 
(WE) 
C 44 
69 
[0.78] 
91 
[1.03] 
44 
58 
[0.66] 
74 
[0.84] 
      
Jaffe 
2 
 4 
Kristensen
17
 2007a Sweden C 58 
65 
[0.74] 
82 
[0.93] 
94 
53 
[0.60] 
70 
[0.79] 
107 
51 
[0.58] 
64 
[0.72] 
88 
54 
[0.61] 
70 
[0.79] 
Enzymatic 
3 
Yes
+
 6 
Kristensen
58
 2007b Sweden C 58 
65 
[0.74] 
82 
[0.93]       
218 
53 
[0.60] 
68 
[0.77] 
Enzymatic 
3 
Yes 6 
Lain
59
 2005 USA L 63 
50 
[0.57] 
92 
[1.04] 
63 
51 
[0.58] 
92 
[1.04] 
63 
44 
[0.50] 
99 
[1.12] 
63 
50 
[0.57] 
92 
[1.04] 
Enzymatic 
2 
Yes 9 
Larsson
4
 2008 Sweden L 51 
67 
[0.76] 
86 
[0.97] 
50 
49 
[0.55] 
62 
[0.70] 
51 
46 
[0.52] 
62 
[0.70] 
52 
47 
[0.53] 
72 
[0.81] 
Jaffe 
2 
Yes
+
 6 
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Lockitch
7
 1993 Majority WE L 121 
73 
[0.83] 
94 
[1.06] 
29 
52 
[0.59] 
77 
[0.87] 
29 
50 
[0.57] 
73 
[0.83] 
29 
56 
[0.63] 
87 
[0.98] 
Enzymatic 
2 
Yes 6 
Lohsiriwat
60
 2008 Thailand L 26 
72 
[0.82] 
90 
      
26 
64 
[0.72] 
84 
Jaffe 
3 
Yes 9 
Mahendru
61
 2014 91% WE L 54 
68 
[0.77] 
88 
[1.00] 
54 
53 
[0.60] 
69 
[0.78]       
Not stated 
2 
Yes 7 
Majewska
62
 2010 Poland L 40 
72 
[0.81] 
94 
[1.06] 
40 
50 
[0.56] 
63 
[0.72] 
40 
46 
[0.52] 
60 
[0.68] 
40 
52 
[0.59] 
75 
[0.85] 
Not stated 
3 
Yes 8 
Makuyana
63
 2002 Zimbabwe C LRR 
78 
[0.88] 
121 
[1.37]       
72 
52 
[0.59] 
70 
[0.79] 
Jaffe 
3 
 6 
Matteucci
64
 1997 Italy L 18 
82 
[0.93] 
102 
[1.15] 
18 
64 
[0.72] 
82 
[0.93] 
18 
62 
[0.70] 
78 
[0.88] 
18 
65 
[0.74] 
77 
[0.87] 
Jaffe 
2 
Yes 4 
Milman
65
 2007 Denmark L 164 
75 
[0.85] 
96 
[1.09]    
394 
55 
[0.62] 
71 
[0.80] 
521 
58 
[0.66] 
81 
[0.92] 
Jaffe 
2 
Yes 7 
Milne
66
 2002 UK (WE) L 11 
65 
[0.74] 
95 
[1.07]       
11 
75 
[0.85] 
78 
[0.88] 
Not stated 
3 
Yes 9 
Miri-
Dashe
67
 
2014 Nigeria C 127 
79 
[0.89] 
118 
[1.33] 
43
±
 
46 
[0.52] 
68 
[0.77] 
43
±
 
46 
[0.52] 
59 
[0.67] 
43
±
 
65 
[0.74] 
94 
[1.06] 
Enzymatic 
1 
 6 
Ogueh
68
 2011 UK L 13 
88 
[1.00] 
107 
[1.21] 
12 
78 
[0.88] 
96 
[1.09] 
13 
77 
[0.87] 
105 
[1.19] 
12 
74 
[0.84] 
106 
[1.20] 
Jaffe 
1 
Yes 8 
Pahl
69
 2001 USA C 15 
67 
[0.76] 
83 
[0.94]    
16 
64 
[0.72] 
76 
[0.86]    
Enzymatic 
3 
 7 
Roberts
27
 1996 UK (WE) L 11 
74 
[0.84] 
88 
[1.00]    
16 
54 
[0.61] 
66 
[0.74] 
11 
53 
[0.60] 
63 
[0.71] 
Jaffe 
3 
Yes 9 
Saxena
70
 2012 USA L 12 
71 
[0.8] 
101 
[1.14]    
12 
53 
[0.60] 
77 
[0.87] 
12 
62 
[0.70] 
80 
[0.91] 
Jaffe 
1 
Yes 8 
Schoenmaker
71 2013 Gambia C 10 
59 
[0.67] 
89 
[1.00]       
10 
74 
[0.84] 
68 
[0.77] 
Enzymatic 
1 
 5 
Siddiqui
72
 1993 Pakistan C 30 
69 
[0.79] 
88 
[1.00]       
35 
49 
[0.64] 
58 
[0.76] 
Jaffe 
3 
 7 
Strevens
73
 2002 Sweden C 12 
61 
[0.69] 
83 
[0.94]       
14 
48 
[0.54] 
66 
[0.75] 
Enzymatic 
3 
 6 
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Table 1: Study characteristics. Creatinine values are given as µmol/L [mg/dL]. Cr= creatinine, ULN= upper limit of normal, LRR= laboratory 
reference range, WE=white European, AC=Afro-Caribbean, Med=Mediterranean *Assessment of pregnancy normality: 1=limited data, 
2=exclusion of comorbidity associated with abnormal renal function eg pre-eclampsia, diabetes, vascular disease, 3=specific exclusion of renal 
disease, +but not excluded from study data, $=provided by study author/centre or available from an alternative source and appropriate for 
date of study, ^= women with emesis excluded from extracted data, #= includes 2 study cohorts at different altitude, ±=Total 131 pregnant 
women, distribution between trimesters not recorded,§=mean creatinine data only, upper limit data not derived from interquartile range.  
Van Buul
74
 1995 Netherlands L LRR 
70 
[0.79] 
90 
[1.02] 
66 
59 
[0.67] 
70 
[0.79] 
66 
59 
[0.68] 
70 
[0.79] 
66 
59 
[0.67] 
75 
[0.85] 
Jaffe 
3 
Yes 8 
Vural
75
 1998 Turkey C 15 
63 
[0.72] 
95 
[1.07]       
20 
61 
[0.69] 
73 
[0.83] 
Jaffe 
2 
 4 
de Weerd
76§ 2003 Netherlands L 96 
70 
[0.79] 
 188 
62 
[0.70] 
       
Jaffe 
2 
Yes
+ 
6 
Weissberg
77
 1991 Israel C 9 
77 
[0.87] 
92 
[1.04]       
32 
61 
[0.69] 
71 
[0.81] 
Jaffe 
1 
 5 
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Variable Coefficient  
(95% confidence interval) 
p-value 
Pregnant cohort size* 0.026 (0.002 to 0.049) 0.03 
Cross sectional data 0.064 (-0.082 to 0.211) 0.38 
Year of publication -0.003 (-0.013 to 0.007) 0.52 
Decade of publication (compared to 2010-2017): 
• 1980 
• 1990 
• 2000 
 
0.218 (-0.333 to 0.377) 
-0.044 (-0.300 to 0.211) 
0.059 (-0.096 to 0.214) 
 
0.90 
0.72 
0.44 
Exclusion of renal disease 0.094 (-0.198 to 0.386) 0.52 
Enzymatic method for creatinine (compared to 
Jaffe method) 
-0.069 (-0.286 to 0.319) 0.91 
Black ethnicity -0.266 (-0.592 to 0.061) 0.11 
 
Table 2: Meta-regression showing impact of each variable on the pregnant:non-
pregnant serum creatinine ratio in the second trimester. The coefficient is a measure 
of the difference in the pregnant:non-pregnant ratio between studies that can be 
attributed to that variable. [*=per 100 women] 
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Table 3: Creatinine in pregnancy as a percentage of non-pregnant value according to 
trimester  
*Example creatinine values are based on a typical value for non-pregnant females of 
67.5µmol/L [0.76mg/dL], and an upper limit of 90µmol/L [1.02mg/dL].12  
#19 studies (816 creatinine measures) inform the mean value and 18 studies (628 
creatinine measures) inform the upper limit. CI=confidence interval. 
  
Trimester 1
st
 2
nd
 3
rd
 
Number of included studies 19# 22 30 
Number of creatinine measures in pregnancy 816# 1183 2422 
Mean creatinine in pregnancy as % of non-
pregnant mean value (95% CI) 
84% 
(76-90) 
77% 
(72-83) 
80% 
(77-84) 
Example mean creatinine* 
56µmol/L   
[0.63mg/dL] 
52µmol/L 
[0.59mg/dL] 
54µmol/L 
[0.61mg/dL] 
Upper limit creatinine as 
% of non-pregnant upper limit based on a 95% 
reference range (95% CI) 
85% 
(76-93) 
80% 
(73-89) 
86% 
(83-89) 
Example upper limit creatinine* 
76µmol/L 
[0.86mg/dL] 
72µmol/L 
[0.81mg/dL] 
77µmol/L 
[0.87mg/dL] 
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Figure legends 
 
Figure 1: Flow diagram of the identification process for eligible studies 
 
Figure 2: Pregnant:non-pregnant ratio for the upper limit of serum creatinine. 
Squares represent the point estimate of the ratio for each study, sized according to 
the study weight (geometric mean product of pregnant and non-pregnant sample 
size). Confidence intervals are not available due to the complexity of determining the 
precision of a ratio value. Overall is the summary value and 95% confidence interval 
generated by the bootstrapping technique for each trimester.  
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Figure 1: Flow diagram of the identification process for eligible studies 
 
 
 
 
 
 
 
 
 
 
Records identified through 
database searching 
(n=3409)  
Additional records identified 
through other sources 
(n=11) 
Records after duplicates removed 
(n=3297) 
Title/Abstract screened 
(n=3267) 
Records excluded 
(n=3033) 
Full-text articles assessed 
for eligibility 
(n=234) 
Full-text articles excluded: 
No serum creatinine data (n=66) 
No non-pregnant control (n=63) 
Duplicate data (n=16) 
Abnormal pregnancy (n=15) 
Abnormal control (n=2) 
Review article (n=6) 
<6 weeks post-partum (n=6) 
No pregnancy data (n=2) 
Insufficient measure of data 
spread (n=6) 
Non-human study (n=1) 
Historical data (n=2) 
Studies included 
(n=49) 
1
st
 trimester: 
22 studies 
1699 creatinine 
measurements
2
nd
 trimester: 
28 studies 
2982 creatinine 
measurements 
3
rd
 trimester: 
40 studies 
3978 creatinine 
measurements 
Unavailable 
(n=30) 
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